EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

High‐Density Lipoprotein‐Associated Cholesterol Abnormalities in a Clinical Outcomes Study of Dysferlin‐Deficient Limb–Girdle Muscular Dystrophy Type R2

Zoe White, Laura Rufibach, Heather Gordish Dressman, Heather Hilsden, Dan Cox, Simone Spuler, John W Day, Kristi J Jones, Diana X Bharucha-Goebel, Emmanuelle Salort-Campana, Alan Pestronk, Maggie C Walter und 10 weitere

Journal of Cachexia, Sarcopenia and Muscle · 2025

DOI: 10.1002/jcsm.70042 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2025. Verfasst von Zoe White und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Pharmacology & Therapeutics, University of British Columbia (UBC), Vancouver, Canada. Hauptthemen laut MEDLINE: Muscular Dystrophies, Limb-Girdle, Dysferlin, Cholesterol, Cholesterol, HDL. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jain Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Limb–girdle muscular dystrophy (MD) type R2 (LGMDR2, formerly LGMD2B) is an autosomal recessive form of MD caused by variants in the dysferlin gene, DYSF . It leads to slow proximal and distal muscle weakening that generally results in loss of ambulation around early adulthood but without the lethal cardiorespiratory dysfunction observed in the more severe Duchenne MD. How loss of dysferlin causes muscle fibre death is poorly understood, but recent evidence suggests a link between muscle wasting and loss of muscle cholesterol homeostasis with circulating lipoprotein abnormalities in many forms of MD.

Methods

Cross‐sectional circulating total cholesterol (CHOL), high‐density lipoprotein‐associated cholesterol (HDL‐C), non‐HDL‐C, creatine kinase (CK), transaminase levels and bilirubin were collected as part of the Jain Clinical Outcomes Study of Dysferlinopathy, a large multicentre LGMDR2 patient cohort ( N = 188), along with ambulatory function values.

Results

We report that 43%, 49% and 50% of male patients were found to have abnormal circulating CHOL, HDL‐C and non‐HDL‐C levels, respectively, whereas in female patients 39%, 37% and 30% of values were in the abnormal range. Overall, 68% of the total cohort had at least one abnormal cholesterol value (78% of males and 60% of females) and 89% of male CHOL/HDL‐C ratios were in the suboptimal range (above 3.5). Although most patients were ambulant, the severity of circulating lipid abnormalities did not correlate with early loss of ambulation. Transaminase levels were lower in late‐stage LGMDR2 samples, whereas bilirubin remained unchanged, suggesting a low muscular mass rather than hepatic origin and the absence of major liver damage.

Conclusions

Data from the largest natural history cohort of LGMDR2 patients support the concept that dyslipidemia is a comorbidity of LGMDR2, and the causal role of cholesterol abnormalities in muscle death should be further investigated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophies, Limb-GirdleDysferlinCholesterolCholesterol, HDLHumansMaleFemaleAdultAdolescentMiddle AgedYoung AdultCross-Sectional Studies

Stichwörter der Autor:innen

cholesteroldysferlindyslipidemiamuscular dystrophy

Substanzen

DysferlinCholesterolCholesterol, HDL

Autor:innen und Institutionen

  • Department of Anesthesiology, Pharmacology & Therapeutics, University of British Columbia (UBC), Vancouver, Canada.
  • UBC Centre for Heart Lung Innovation, St. Paul's Hospital, Vancouver, Canada.
  • Jain Foundation, Seattle, Washington, USA.
  • Center for Translational Science, Division of Biostatistics and Study Methodology, Children's National Health System, Washington, District of Columbia, USA.
  • Pediatrics, Epidemiology and Biostatistics, George Washington University, Washington, District of Columbia, USA.
  • The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.

ORCID-Profile: Pascal Bernatchez

Förderung

  • Jain Foundation

Zitieren

APA

White, Z., Rufibach, L., Dressman, H. G., Hilsden, H., Cox, D., Spuler, S., Day, J. W., Jones, K. J., Bharucha-Goebel, D. X., Salort-Campana, E., Pestronk, A., Walter, M. C., Paradas, C., Stojkovic, T., Mori-Yoshimura, M., Bravver, E., Diaz-Manera, J., Pegoraro, E., Mendell, J. R., …, & Bernatchez, P. (2025). High‐Density Lipoprotein‐Associated Cholesterol Abnormalities in a Clinical Outcomes Study of Dysferlin‐Deficient Limb–Girdle Muscular Dystrophy Type R2. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.70042

Vancouver

White Z, Rufibach L, Dressman HG, Hilsden H, Cox D, Spuler S, et al. High‐Density Lipoprotein‐Associated Cholesterol Abnormalities in a Clinical Outcomes Study of Dysferlin‐Deficient Limb–Girdle Muscular Dystrophy Type R2. Journal of Cachexia, Sarcopenia and Muscle. 2025. doi:10.1002/jcsm.70042

BibTeX
@article{White2025,
  author = {White, Zoe and Rufibach, Laura and Dressman, Heather Gordish and Hilsden, Heather and Cox, Dan and Spuler, Simone and Day, John W and Jones, Kristi J and Bharucha-Goebel, Diana X and Salort-Campana, Emmanuelle and Pestronk, Alan and Walter, Maggie C and Paradas, Carmen and Stojkovic, Tanya and Mori-Yoshimura, Madoka and Bravver, Elena and Diaz-Manera, Jordi and Pegoraro, Elena and Mendell, Jerry R and Jain COS Consortium, Jain COS Consortium and Straub, Volker and Bernatchez, Pascal},
  title = {High‐Density Lipoprotein‐Associated Cholesterol Abnormalities in a Clinical Outcomes Study of Dysferlin‐Deficient Limb–Girdle Muscular Dystrophy Type R2},
  journal = {Journal of Cachexia, Sarcopenia and Muscle},
  year = {2025},
  doi = {10.1002/jcsm.70042}
}
Kostenlos starten →